CytoMed Therapeutics (GDTC) Equity Average (2022 - 2025)

CytoMed Therapeutics (GDTC) has disclosed Equity Average for 4 consecutive years, with $6.0 million as the latest value for Q4 2025.

  • Quarterly Equity Average fell 20.1% to $6.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $6.0 million through Dec 2025, down 20.1% year-over-year, with the annual reading at $5.9 million for FY2025, 20.38% down from the prior year.
  • Equity Average hit $6.0 million in Q4 2025 for CytoMed Therapeutics, down from $7.6 million in the prior quarter.
  • In the past five years, Equity Average ranged from a high of $7.6 million in Q4 2024 to a low of $1.2 million in Q4 2022.
  • Historically, Equity Average has averaged $4.8 million across 4 years, with a median of $5.2 million in 2023.
  • Biggest five-year swings in Equity Average: soared 275.22% in 2023 and later dropped 20.1% in 2025.
  • Year by year, Equity Average stood at $1.2 million in 2022, then skyrocketed by 275.22% to $4.4 million in 2023, then skyrocketed by 72.87% to $7.6 million in 2024, then dropped by 20.1% to $6.0 million in 2025.
  • Business Quant data shows Equity Average for GDTC at $6.0 million in Q4 2025, $7.6 million in Q4 2024, and $4.4 million in Q4 2023.